

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Yunkang Group Limited

云康集团有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2325)

POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON DECEMBER 27, 2024

Reference is made to the circular (the “**Circular**”) and the notice (the “**Notice**”) of the extraordinary general meeting (the “**EGM**”) of Yunkang Group Limited (the “**Company**”), both dated December 5, 2024, in relation to, among other things, the 2025-2027 Reagents, Consumables and Equipment Procurement Framework Agreement, the transactions contemplated thereunder and the proposed annual caps. Unless the context requires otherwise, terms used herein shall have the same meanings as those defined in the Circular.

The board of directors of the Company (the “**Board**”) is pleased to announce that the proposed resolution as set out in the Notice was duly passed by the Independent Shareholders by way of poll at the EGM held on December 27, 2024.

The poll results in respect of the resolution proposed at the EGM are as follow:

ORDINARY RESOLUTION		No. of Votes (%)	
		For	Against
1.	“ THAT (1) the 2025-2027 Reagents, Consumables and Equipment Procurement Framework Agreement (as defined in the circular of the Company dated December 5, 2024) (the “ Circular ”) entered into by and between the Company and Daan Gene Co., Ltd. (廣州達安基因股份有限公司) (“ Da An Gene ”) dated November 11, 2024 (a copy of which has been produced to the Extraordinary General Meeting and marked “A” and initialed by a Director for the purpose of identification) (details of which are set out in the Circular) relating to the procurement of reagents, consumables and equipment by the Company and its subsidiaries (the “ Group ”) from Da An Gene and its subsidiaries (“ Da An Gene Group ”), and all the transactions contemplated thereunder be and are hereby approved, ratified and confirmed; and (2) the proposed annual caps for the 2025-2027 Reagents, Consumables and Equipment Procurement Framework Agreement for the years ending December 31, 2025, 2026 and 2027 in the amounts of RMB41.083 million, RMB51.354 million and RMB64.193 million, respectively, be and are hereby approved and confirmed; and THAT any one or more directors of the Company be and are hereby authorized to do all such things and execute all such documents as they in their absolute discretion deem fit or appropriate to give effect to the 2025-2027 Reagents, Consumables and Equipment Procurement Framework Agreement and the implementation of all the transactions contemplated thereunder.”	256,200,500 100.00%	0 0.00%

As more than 50% of the eligible votes were cast in favor of the above ordinary resolution, the above ordinary resolution was duly passed by the shareholders of the Company.

As at the date of the EGM, the total number of issued shares of the Company was 621,250,500 Shares. The trustee of the Company's restricted share unit scheme adopted on November 23, 2022, who holds a total of 35,905,846 Shares, was required to abstain and had abstained from voting on the resolution at the EGM. As disclosed in the Circular, Daan International Holdings Limited, a subsidiary of Da An Gene and a controlling shareholder of the Company, holds as to a total of 209,783,000 Shares, was required to abstain and had abstained from voting on the resolution at the EGM. Accordingly, there were in aggregate 375,561,654 Shares entitling the holders to attend and vote for or against the resolution at the EGM. Save as disclosed above, no Shareholders were required under the Listing Rules to abstain from voting on the resolution at the EGM and no Shareholders were entitled to attend and abstain from voting in favor as set out in Rule 13.40 of the Listing Rules.

No parties have stated their intention in the Circular to vote against or to abstain from voting on the proposed resolution at the EGM.

The Company's share registrar in Hong Kong, Tricor Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

Mr. Zhang Yong as chairman and executive Director, Dr. Wang Pinghui and Dr. Wang Ruihua, as non-executive Directors, and Mr. Yu Shiyou, Mr. Lan Fenghui and Mr. Xie Shaohua, as independent non-executive Directors attended the EGM in person or by electronic means.

By order of the Board
Yunkang Group Limited
Zhang Yong
Chairman

Guangzhou, the PRC
December 27, 2024

As at the date of this announcement, the Board comprises Mr. Zhang Yong as chairman and executive Director; Ms. Huang Luo, Dr. Wang Pinghui and Dr. Wang Ruihua as non-executive Directors; and Mr. Yu Shiyou, Mr. Lan Fenghui and Mr. Xie Shaohua as independent non-executive Directors.